1921
Volume 90, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Between 2000 and 2010, Médecins Sans Frontières diagnosed and treated 4,831 patients with visceral leishmaniasis (VL) in the Pokot region straddling the border between Uganda and Kenya. A retrospective analysis of routinely collected clinical data showed no marked seasonal or annual fluctuations. Males between 5 and 14 years of age were the most affected group. Marked splenomegaly and anemia were striking features. An rK39 antigen-based rapid diagnostic test was evaluated and found sufficiently accurate to replace the direct agglutination test and spleen aspiration as the first-line diagnostic procedure. The case-fatality rate with sodium stibogluconate as first-line treatment was low. The VL relapses were rare and often diagnosed more than 6 months post-treatment. Post-kala-azar dermal leishmaniasis was rare but likely to be underdiagnosed. The epidemiological and clinical features of VL in the Pokot area differed markedly from VL in Sudan, the main endemic focus in Africa.

[open-access] This is an Open Access article distributed under the terms of the American Society of Tropical Medicine and Hygiene's Re-use License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.13-0150
2014-01-08
2017-09-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/90/1/33.html?itemId=/content/journals/10.4269/ajtmh.13-0150&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2010. Control of the Leishmaniases. Report of a meeting of the WHO Expert Committee on Control of Leishmaniases, Geneva, 22–26 March 2010. WHO Technical Report Series; no. 949.
  2. Elnaiem DA, , 2011. Ecology and control of the sand fly vectors of Leishmania donovani in East Africa, with special emphasis on Phlebotomus orientalis . J Vector Ecol 36: S23S31.[Crossref]
  3. Gebre-Michael T, Malone JB, Balkew M, Ali A, Berhe N, Hailu A, Herzi AA, , 2004. Mapping the potential distribution of Phlebotomus martini and P. orientalis (Diptera: Psychodidae), vectors of kala-azar in East Africa by use of geographic information systems. Acta Trop 90: 7386.[Crossref]
  4. Jamjoom MB, Ashford RW, Bates PA, Chance ML, Kemp SJ, Watts PC, Noyes HA, , 2004. Leishmania donovani is the only cause of visceral leishmaniasis in East Africa; previous descriptions of L. infantum and “L. archibaldi” from this region are a consequence of convergent evolution in the isoenzyme data. Parasitology 129: 399409.[Crossref]
  5. Fendall NR, , 1961. The spread of kala-azar in Kenya. East Afr Med J 38: 417419.
  6. Fendall NR, , 1950. Kala-azar in the Kitui Reserve. East Afr Med J 27: 291296.
  7. Fendall NR, McKinnon JA, , 1956. Kala-azar in the Baringo District of Kenya; progress report. J Trop Med Hyg 59: 208212.
  8. Mutero CM, Mutinga MJ, Ngindu AM, Kenya PR, Amimo FA, , 1992. Visceral leishmaniasis and malaria prevalence in West Pokot District, Kenya. East Afr Med J 69: 38.
  9. Wykoff DE, Barnley GR, Winn MM, , 1969. Studies on kala-azar in Uganda–entomological observations. East Afr Med J 46: 204207.
  10. Kager PA, Rees PH, , 1983. Splenic aspiration. Review of the literature. Trop Geogr Med 35: 111124.
  11. Mueller Y, Nguimfack A, Cavailler P, Couffignal S, Rwakimari JB, Loutan L, Chappuis F, , 2008. Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda. Ann Trop Med Parasitol 102: 1119.[Crossref]
  12. Mueller Y, Mbulamberi DB, Odermatt P, Hoffmann A, Loutan L, Chappuis F, , 2009. Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda. Trop Med Int Health 14: 910917.[Crossref]
  13. Chappuis F, Mueller Y, Nguimfack A, Rwakimari JB, Couffignal S, Boelaert M, Cavailler P, Loutan L, Piola P, , 2005. Diagnostic accuracy of two rK39 antigen-based dipsticks and the formol gel test for rapid diagnosis of visceral leishmaniasis in northeastern Uganda. J Clin Microbiol 43: 59735977.[Crossref]
  14. Cunningham J, Hasker E, Das P, el Safi S, Goto H, Mondal D, Mbuchi M, Mukhtar M, Rabello A, Rijal S, Sundar S, Wasunna M, Adams E, Menten J, Peeling R, Boelaert M, , 2012. A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Infect Dis 55: 13121319.[Crossref]
  15. Chappuis F, Rijal S, Soto A, Menten J, Boelaert M, , 2006. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ 333: 723.[Crossref]
  16. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Royce C, Russo R, Sundar S, Alvar J, , 2006. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 43: 917924.[Crossref]
  17. Seaman J, Boer C, Wilkinson R, de Jong J, de Wilde E, Sondorp E, Davidson R, , 1995. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 21: 188193.[Crossref]
  18. Mueller M, Ritmeijer K, Balasegaram M, Koummuki Y, Santana MR, Davidson R, , 2007. Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans R Soc Trop Med Hyg 101: 1924.[Crossref]
  19. Ritmeijer K, Davidson RN, , 2003. Royal Society of Tropical Medicine and Hygiene joint meeting with Medecins Sans Frontieres at Manson House, London, 20 March 2003: field research in humanitarian medical programmes. Medecins Sans Frontieres interventions against kala-azar in the Sudan, 1989–2003. Trans R Soc Trop Med Hyg 97: 609613.[Crossref]
  20. Veeken H, Ritmeijer K, Seaman J, Davidson R, , 2000. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health 5: 312317.[Crossref]
  21. Musa AM, Younis B, Fadlalla A, Royce C, Balasegaram M, Wasunna M, Hailu A, Edwards T, Omollo R, Mudawi M, Kokwaro G, El-Hassan A, Khalil E, , 2010. Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study. PLoS Negl Trop Dis 4: e855.[Crossref]
  22. Zijlstra EE, Khalil EA, Kager PA, El-Hassan AM, , 2000. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis. Br J Dermatol 143: 136143.[Crossref]
  23. Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, Kirigi G, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tafes H, Mekonnen Y, Makonnen E, Ndegwa S, Sagaki P, Kimutai R, Kesusu J, Owiti R, Ellis S, Wasunna M, , 2012. Sodium stibogluconate (SSG) and paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomized controlled trial. PLoS Negl Trop Dis 6: e1674.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.13-0150
Loading
/content/journals/10.4269/ajtmh.13-0150
Loading

Data & Media loading...

  • Received : 21 Mar 2013
  • Accepted : 06 Oct 2013

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error